OBJECTIVE: To describe the methodology of the first NIH-funded clinical trial for seniors with comorbid depression and chronic low back pain. METHODS: Randomized controlled effectiveness trial using stepped care methodology. Participants are ≥60 years old. Phase 1 (6 weeks) is open treatment with venlafaxine xr 150 mg/day and supportive management (SM). Response is 2 weeks of PHQ-9 ≤5 and at least 30% improvement in the average numeric rating scale for pain. Nonresponders progress to phase 2 (14 weeks) in which they are randomized to high-dose venlafaxine xr (up to 300 mg/day) with problem solving therapy for depression and pain (PST-DP) or high-dose venlafaxine xr and continued SM. Primary outcomes are the univariate pain and depression response and both observed and self-reported disability. Survival analytic techniques will be used, and the clinical effect size will be estimated with the number needed to treat. We hypothesize that self-efficacy for pain management will mediate response for subjects randomized to venlafaxine xr and PST-DP. RESULTS: Not applicable. CONCLUSIONS: The results of this trial will inform the care of these complex patients and further understanding of comorbid pain and depression in late life. Wiley Periodicals, Inc.
RCT Entities:
OBJECTIVE: To describe the methodology of the first NIH-funded clinical trial for seniors with comorbid depression and chronic low back pain. METHODS: Randomized controlled effectiveness trial using stepped care methodology. Participants are ≥60 years old. Phase 1 (6 weeks) is open treatment with venlafaxine xr 150 mg/day and supportive management (SM). Response is 2 weeks of PHQ-9 ≤5 and at least 30% improvement in the average numeric rating scale for pain. Nonresponders progress to phase 2 (14 weeks) in which they are randomized to high-dose venlafaxine xr (up to 300 mg/day) with problem solving therapy for depression and pain (PST-DP) or high-dose venlafaxine xr and continued SM. Primary outcomes are the univariate pain and depression response and both observed and self-reported disability. Survival analytic techniques will be used, and the clinical effect size will be estimated with the number needed to treat. We hypothesize that self-efficacy for pain management will mediate response for subjects randomized to venlafaxine xr and PST-DP. RESULTS: Not applicable. CONCLUSIONS: The results of this trial will inform the care of these complex patients and further understanding of comorbid pain and depression in late life. Wiley Periodicals, Inc.
Authors: Sati Mazumdar; Patricia R Houck; Kenneth S Liu; Benoit H Mulsant; Bruce G Pollock; Mary Amanda Dew; Charles F Reynolds Journal: J Psychiatr Res Date: 2002 May-Jun Impact factor: 4.791
Authors: M Pahor; J M Guralnik; J Y Wan; L Ferrucci; B W Penninx; A Lyles; S Ling; L P Fried Journal: Am J Public Health Date: 1999-06 Impact factor: 9.308
Authors: Ellen M Whyte; James Basinski; Panthea Farhi; Mary Amanda Dew; Amy Begley; Benoit H Mulsant; Charles F Reynolds Journal: J Clin Psychiatry Date: 2004-12 Impact factor: 4.384
Authors: Wenjing Wei; Helmet T Karim; Chemin Lin; Akiko Mizuno; Carmen Andreescu; Jordan F Karp; Charles F Reynolds; Howard J Aizenstein Journal: J Clin Psychiatry Date: 2018-10-23 Impact factor: 4.384